suggests the Moderna vaccine’s advantage in terms of long-term protection. In multiple independent studies, significantly lower antibody levels and more vaccine breakthrough infections have been ...

and clinics across the country," a spokesperson for Pfizer told Newsweek in an email. More From Newsweek Vault: Compare the ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Pfizer and Moderna’s messenger RNA-based shots have ... from the three vaccine makers from June through December pales in ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Pfizer's and Moderna's vaccines are each more than 90% effective. But it's difficult to compare the companies' trials side by side because they happened at different stages in the pandemic and in ...

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent dispute centring on their mRNA-based vaccines for COVID-19. Moderna fired the first volley back in August ...

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.

It will compare the shot against a ... to a current vaccine due to start shortly. Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property ...

Top vaccine stocks for investors to consider include Pfizer and Moderna. Other vaccine stocks to watch include Bavarian Nordic and Emergent BioSolutions. Key findings are powered by ChatGPT and ...

But what Sam Bankman-Fried did pales in comparison, in my opinion, to the fraud that was perpetrated by Moderna and Pfizer. TRAVIS: Not only did the shots fail, via fraud you were encouraged and ...